naldemedine

01/01/2021 - "Naldemedine treatment was associated with a rapid and sustained clinically relevant improvement in patient-reported outcomes, indicating improvement in opioid-induced constipation-related symptoms and QOL. "
03/01/2019 - "Naldemedine 0.2 mg daily significantly improved symptoms in patients with opioid-induced constipation and was generally well tolerated. "
05/01/2018 - "Naldemedine significantly increased bowel movement frequency, improved symptomatic burden of opioid-induced constipation, and increased patients' quality of life vs placebo."
01/01/2017 - "Naldemedine effective in treating opioid-induced constipation."
03/01/2019 - "Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis."

06/01/2018 - "Naldemedine provided effective and timely symptomatic relief from OIC and improved the QOL of subjects with OIC and cancer. "
12/01/2017 - "Conclusion Once-daily oral naldemedine 0.2 mg effectively treated OIC and was generally well tolerated in patients with OIC and cancer."
01/01/2022 - "This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. "
02/01/2019 - "Our final review included five randomized clinical trials (1751 participants in total), three trials observed naldemedine for the treatment of OIC in non-cancer patients and two trials in cancer patients. "
01/01/2023 - "Setting/Subjects: Japanese cancer patients with ECOG performance status 3 or 4 who received naldemedine. "

05/01/2022 - "This PMS indicates that naldemedine is well tolerated and effective in patients of various backgrounds in routine clinical practice who have OIC and cancer pain. "
01/01/2020 - "This integrated analysis confirmed that OIC treatment with naldemedine 0.2 mg was generally well tolerated and effective in patients aged ≥ 65 years with chronic non-cancer pain. "
01/01/2020 - "Patients age 18-80 years with chronic non-cancer pain (CNCP) and OIC received oral naldemedine 0.2 mg or placebo once daily. "
09/01/2023 - "Naldemedine was well tolerated and effective in patients with opioid-induced constipation and cancer pain regardless of the subgroups investigated."
01/01/2021 - "Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives."

01/01/2018 - "Based on the available data, naldemedine appears to be an effective and safe drug for the treatment of OIC in adults with chronic noncancer pain."
10/01/2019 - "These findings should assist clinicians counseling patients with chronic noncancer pain on expectations when initiating naldemedine for OIC."
01/01/2019 - "Eligible Japanese adults with OIC and chronic noncancer pain received once-daily oral naldemedine 0.2 mg for 48 weeks, irrespective of food intake. "
01/01/2018 - "This review aimed to summarize the literature on naldemedine, the third PAMORA to gain US Food and Drug Administration (FDA) approval for the treatment of OIC in adults with chronic noncancer pain-related syndromes. "
10/01/2019 - "Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials."

01/01/2022 - "Naldemedine showed significant and sustained improvement in frequency of bowel movements, quality of life, and constipation-related symptoms. "
01/01/2021 - "The majority of patients treated with naldemedine reported markedly or moderately improved satisfaction with constipation and abdominal symptoms on the Subject Global Satisfaction questionnaire. "
01/01/2021 - "The effect of naldemedine was determined according to the degree of constipation. "
07/01/2019 - "Naldemedine was also associated with improvements in patient-rated constipation-related symptoms and quality of life. "
05/01/2018 - "Sustained significant improvements in bowel movement frequency and overall constipation-related symptoms and quality of life were observed with naldemedine (P ≤ 0.0001 vs placebo at all time points). "